ImmunArray is a molecular diagnostics company dedicated to the development of novel blood based tests to support the diagnosis and management of complex acute and chronic immune-mediated and neurodegenerative diseases.
Poster Presentation: “The Autoimmune Discovery iCHIP Distinguishes Healthy Individuals (HC) from Those with SLE, Rheumatoid Arthritis (RA), Scleroderma (SSc), Sjogren’s Syndrome (SS), and the Anti-Phospholipid Syndrome (APS)”
Alliance with China-based diagnostic company to support joint clinical studies and prepare for diagnostic product introduction in Chinese markets
Richmond, VA., July 10, 2017 – ImmunArray, a privately held molecular device company dedicated to the development of novel, blood-based in vitro diagnostic tests, and Kindstar Global Co., Ltd., a specialty clinical testing company based in Wuhan, China with locations throughout mainland China, have forged a partnership involving shared clinical studies and the launch of ImmunArray’s lupus rule-out test in China as the initial product offering.
Molecular diagnostic company’s research into blood-based diagnosis of traumatic brain injury presented at national conferences
Richmond, Va., July 18, 2016 – Clinical research into ways in which blood-based biomarkers can provide precise and timely diagnosis of traumatic brain injury (TBI) is leading to encouraging results, with some studies resulting in a diagnosis with more than 95 percent sensitivity and specificity.
We are a clinically driven company guided by leadership physician input at each stage of our development. We welcome questions and open discussions, and look forward to continuing to work with our collaborators and partners around the globe.